Currently, the approved indications for the combination of dabrafenib and trametinib in China are: (1) for patients with unresectable or metastatic melanoma positive for the BRAF V600 mutation; (2) as adjuvant therapy following complete resection in patients with stage III melanoma positive for the BRAF V600 mutation; and (3) for patients with metastatic NSCLC positive for the BRAF V600 mutation. Here, BRAF is linked to non-small cell lung carcinoma.